PFE“>
When high yield signals high risk
A 7% yield is a red flag in a market full of green. Pfizer trades at 8.1 times forward earnings-a number that screams “caution.” Earnings are projected to decline 3% annually through 2029. Peers like Johnson & Johnson (2.9%) and Merck (3.9%) offer lower yields but stronger balance sheets. AbbVie’s 3.1% isn’t bad either. These companies trade stability for greed. Pfizer’s dividend is a gamble that management can outwit patent cliffs and pipeline failures. It’s a bet with no guaranteed payout.
The dividend is safe through 2026, perhaps with token raises. But long-term? The board will face choices. A cut isn’t imminent, but growth is a fantasy. Buying Pfizer for its dividend is betting against entropy itself. The 7% yield is a warning label, not a promise. So it goes.
The payout will survive the next few years, maybe with small increases. But the long-term outlook is a question mark. Pfizer’s 7% dividend is less a gift than a dare. Investors are invited to dance with the devil-on a sinking ship. 🚩
Read More
- Gold Rate Forecast
- ETH PREDICTION. ETH cryptocurrency
- XRP: A Lingering Question
- fuboTV Stock Soars: A Value Investor’s Diary
- You Won’t Believe What’s Inside Universal Epic Universe
- Jeremy Renner Returns in Mayor of Kingstown Season Four on Paramount+ October 26
- Palantir’s Earnings: A Test of Valuation vs. Reality
- Should You Buy XRP (Ripple) While It’s Under $10?
- AMD’s Rise: A Fleeting Mirage?
- Распадская акции прогноз. Цена RASP
2025-09-01 13:20